dence of single SNP associations in either diabetic or nondiabetic ESRD; although nominal evidence of association with all-cause ESRD was observed with a two SNP (p = 0.022) and three SNP (p = 0.023) haplotype, both containing SNPs rs7490924 and rs2391335 in intron 1. Conclusions: Although an attractive positional candidate gene, polymorphisms in the EFNB2 gene do not appear to contribute in a substantial way to non-diabetic, diabetic or all-cause ESRD susceptibility in African-Americans. Additional genes within the chromosome 13q33 linkage interval are likely contributors to African-American non-diabetic ESRD.
Introduction
Familial aggregation of end-stage renal disease (ESRD) is observed worldwide [1] and is independent from the prevalence of diabetes and hypertension within families [2] . African-American men and women demonstrate the strongest familial aggregation of ESRD, with a 2.5-to 3-fold higher risk when compared to European-Americans [3] . These factors strongly implicate the presence of renal failure susceptibility genes.
Three genome scans have been published in AfricanAmerican families enriched for multiple members with ESRD. These reports focused on diabetic, non-diabetic (hypertensive nephrosclerosis and glomerular diseases) and all-cause etiologies of ESRD [4] [5] [6] . Significant evidence for linkage to ESRD was detected on chromosome 13q33 in both the non-diabetic and all-cause ESRD genome scans. Thus, a renal failure susceptibility gene(s) may reside under this linkage peak.
The ephrin-B2 (EFNB2) gene is located on 13q33 and contains 5 exons spanning 45 kb. Splicing of these exons resulted in a 4,317-bp transcript encoding a 333 amino acid protein. The ephrin-B2 ligand is expressed in the developing nephron and interactions between ephrin-B2 receptor tyrosine kinases and transmembrane-type ephrin-B2 ligands appear to play an important role in vasculogenesis in the developing embryo [7, 8] . Ephrin-B2 also induces migration of adult endothelial cells and promotes angiogenesis via the phosphatidylinositol-3 (PI3) kinase pathway [9] . In related studies, ephrin-B1 was recently shown to co-localize with CD2-associated protein (CD2AP) and nephrin at the podocyte slit diaphragm and plays an important role in maintaining barrier function at the slit diaphragm [10] and ephrin B4 receptor kinase transgenic mice develop glomerulopathy, manifested by fused afferent and efferent arterioles bypassing the glomeruli (aglomerular vascular shunts) [11] .
Diseases of small intrarenal arterioles and arteries have been implicated in the development of arteriolar nephrosclerosis (hypertensive renal disease). Hypertensive ESRD is more often diagnosed in African-Americans compared to European-Americans, with a 4-fold higher incidence rate nationally and a twenty-fold higher incidence rate in the southeastern US [12] . The small blood vessel injury observed in arteriolar nephrosclerosis fails to correlate with systemic blood pressure [13, 14] , suggesting the presence of an innate renal blood vessel disease that secondarily leads to systemic hypertension with resultant renal failure. In order to determine whether EFNB2 , a positional and functional candidate gene for nephropathy susceptibility was involved in the pathogenesis of kidney failure, we performed an association analysis of the EFNB2 gene in African-Americans with ESRD.
Methods

Participants
Self-reported African-Americans born in North Carolina, South Carolina, Georgia, Virginia or Tennessee formed the study population. Peripheral blood specimens for DNA extraction were collected from unrelated, prevalent patients performing hemodialysis in Winston-Salem, Greensboro and Hickory, North Carolina. Medical records were reviewed by a single investigator (B. I.F.). Non-diabetic subjects with ESRD attributed to hypertension on the CMS 2728 form and with hypertension preceding initiation of renal replacement therapy and hypertensive target organ damage (retinopathy or left ventricular hypertrophy), or with chronic glomerulonephritis (proteinuria detected on dipstick or quantitated urine specimen) were diagnosed as having non-diabetic ESRD. Type 2 diabetic ESRD was diagnosed in subjects whose diabetes developed after the age of 34 years, with 6 5 years diabetes duration prior to dialysis onset, in the presence of diabetic retinopathy and/or proteinuria exceeding 500 mg/24 h. Cases with polycystic kidney disease, hereditary nephritis, urologic diseases and surgical nephrectomy were excluded.
Healthy, unrelated non-diabetic African-Americans who were born in one of the above five states served as controls. Control subjects denied a personal or family history (in first-degree relatives) of diabetes or kidney disease (kidney disease defined as kidney failure, dialysis treatments or kidney transplantation). The study was approved by the Institutional Review Board at the Wake Forest University School of Medicine and met the criteria outlined in the Declaration of Helsinki. All participants provided written informed consent. DNA from these participants was extracted using Puregene (Gentra, Minneapolis, Minn., USA). Table 1 contains demographic data from study participants. Thirtynine unrelated European-American (EA) controls were recruited, as described for the African-American controls, and DNA was obtained from 44 Yoruba Nigerians from the National Institute of General Medicine Sciences (NIGMS) Human Variation Collection (Coriell Repositories, Camden, N.J., USA).
SNP Selection and Genotyping
Twenty-eight haplotype tagging SNPs were chosen for genotyping based on linkage disequilibrium (LD) information from the HapMap Yoruba in Ibidan Nigerian dataset to maximally capture (r 2 1 0.80) common variants (minor allele frequency 1 5%). Selected SNPs were: rs9520087, rs3742160, rs4399422, rs9301140, rs9301141, rs9514540, rs11069646, rs9587148, rs7983579, rs7983611, rs9514543, rs8002701, rs8001826, rs7327929, rs11840214, rs9520090, rs9520091, rs9520092, rs7320751, rs4772795, rs9514545, rs7490924, rs2391335, rs2391336, rs2391337, rs2391339, rs8000078 and rs9520094. All SNPs were intronic, with the exception of rs9520087 which was located in the noncoding portion of exon 5. Figure 1 depicts the EFNB2 gene and the relative location of each SNP. These SNPs spanned the entire EFNB2 gene at an average density of 1.43 kb with inter-SNP distances ranging from 22 bp to 6.5 kb. SNP genotyping was performed on a Sequenom Mass Array Genotyping System (Sequenom, San Diego, Calif., USA).
Genotyping for Admixture Analysis
Seventy diallelic Admixture Informative Markers (AIMs) were genotyped to determine whether population substructure biased our conclusions [15] . The 44 YRI, 39 EA controls, 361 African-American controls, and 730 African-American ESRD samples were genotyped using Illumina Inc's Custom Genotyping Services (San Diego, Calif., USA) or using the Sequenom Mass Array (San Diego, Calif., USA). A power analysis was performed to determine the odds ratio (OR) detectable with 710 ESRD cases and 361 controls, assuming a prevalence of 2.5%. Computations were completed using QUANTO (version 1.1.1) for ␣ = 0.05 and ␣ = 0.001, over a range of minor allele frequencies and genetic models (i.e. dominant, additive and recessive).
Statistical Analyses
Statistical analyses to test for Hardy-Weinberg equilibrium (HWE) were determined by calculating a 2 statistic and corresponding p value. Pair-wise LD and single SNP allelic associations were performed using Haploview 3.32 [16] . Dandelion was used to perform haplotypic association analysis [17] and Snpaddmix was used to calculate haplotypic association adjusted for African ancestry proportions as reported in Keene et al. [15] .
Results
Using Tagger [18] , the 28 SNPs that were analyzed captured 94% of the known variation at the EFNB2 locus with an r 2 1 0.80 (mean r 2 = 0.96). In the case and control populations, four SNPs failed to meet HWE; rs3742160 (p = 0.003 controls, p = 0.038 cases), rs9587148 (p = 0.0001 controls, p = 0.0001 cases), rs9514543 (p = 0.002 controls, p = 0.006 cases) and rs11840214 (p = 0.022 controls, p = 0.0018 cases). Two additional SNPs did not conform to HWE, one in the case population rs8002701 (p = 0.021) and one in the control population rs8000078 (p = 0.041). Two SNPs (rs4399422 and rs7983611) were removed from further analysis when they failed to meet genotyping efficiency ( ! 95% genotyping success rate). Genotyping figure 1 , where the absolute value of the inter-SNP D' from the control population is shown. A similar LD structure was observed in the case population (data not shown). Table 2 summarizes allele frequencies and the results of the single SNP allelic association analysis for the African-American ESRD cases and control subjects. Initial analysis did not reveal any single SNP allelic associations with ESRD, however, SNP rs2391335 trended towards association (p = 0.056). This result remained unchanged when adjusted for admixture (p = 0.057).
Following single SNP analysis, haplotypic analysis was performed with Dandelion [17] using 2-and 3-marker moving windows for all-cause ESRD. Nominal evidence of association in a 2-and 3-marker haplotype, both containing the SNPs rs7490924 and rs2391335 in intron 1, was observed. Table 3 describes the association analysis of the significant 2-and 3-SNP haplotypes. The frequency for cases and controls, p value, Z score and OR of each haplotype is presented with the empiric p value for all haplotypes constructed within the interval. Significance within this interval does not appear to be the result of a rare genotype since the significantly associated GT haplotype driving both 2-SNP (p = 0.029) and 3-SNP (haplotype TGT, p = 0.064) ( table 3 ), haplotypic associations is present at a frequency of 18% in cases and 13% in controls. The positive Z statistic of 2.18 and an OR of 1.48 suggest the GT haplotype is a risk haplotype, i.e. associated with increased prevalence of disease.
FRAPPE (Frequentist Estimation of individual ancestry proportion) was used to calculate the proportion of African ancestry in our case and control population [19] . AIMs genotyped in our population revealed a mean African ancestry proportion of 0.792 (SD = 0.110) in controls and 0.807 (SD = 0.108) in ESRD cases. The individual African ancestry proportion data was used as a covariate in the program Snpaddmix [Langefeld and Stiegert, unpubl.] to calculate haplotype analysis. The p values seen in the original analyses did not change significantly, further proving that admixture was not a factor. The p values for the 2-marker (p = 0.022) and 3-marker (p = 0.023) haplotypes remained significant after adjustment for ancestry.
A power analysis was computed to examine the magnitude of the OR plausibly detectable ( table 4 ) . For a SNP with a minor allele frequency of 0.20 and with 0.50 power, 710 ESRD cases and 361 controls can detect an OR = 1.21 and OR = 1.44 for ␣ = 0.05 and ␣ = 0.001, respectively. These estimates are consistent with published ORs for complex genetic traits.
Discussion
Factors other than high blood pressure per se contribute to the development of arteriolar nephrosclerosis or 'hypertension-associated end-stage renal disease'. Two renal biopsy studies demonstrated that the degree of systemic hypertension did not correlate with arterioor arteriolo-nephrosclerosis [13, 14] . Epidemiologic analyses strongly support this conclusion [20] . In addition, strict blood pressure control fails to halt the progression of hypertensive nephropathy in African-Americans, while it appears to do so in Caucasians [21, 22] . The ephrin-B2 ligand (EFNB2) gene is an attractive candidate gene for susceptibility to hypertensive renal failure (e.g. non-diabetic ESRD), since polymorphisms in this gene could lead to arterio-nephrosclerosis. Disease in small arterioles could result in high systemic blood pressures and progressive kidney failure. However, we Ephs and ephrins are membrane-bound proteins that function as receptor-ligand pairs. Angiogenesis, the process of sprouting branches from the immature vascular plexus, differential growth of endothelial cells and recruitment of pericytes and smooth muscle cells, are dependent on the effects of vascular endothelial growth factor (VEGF) , angiopoietins and ephrins [23] . Ephrin-B2 ligand and ephrin-B2 receptor appear to trigger the development of angioblasts into mature endothelial cells that are committed to either an artery or vein lineage [24] . In addition, ephrin-B1 expression has been detected along the glomerular capillary loop, where it is restricted to the glomerular slit diaphragm [10] . Ephrin-B1, nephrin and CD2-associated protein all co-localize at the slit diaphragm and there is extensive evidence supporting ephrin-B1 as playing an important role in maintaining slit diaphragm barrier function [10] . Abnormalities in this barrier lead to proteinuria, a risk factor for progressive renal injury. As a primary defect in small intrarenal arterioles may underlie hypertensive nephrosclerosis in African-Americans, polymorphisms in the EFNB2 gene under the 13q linkage peak could have accounted for development of this disease. However, thorough analysis of this gene using 28 SNPs at best revealed limited evidence for such an association. This leaves open the likelihood that another gene or genes in this region contribute to the evidence of linkage.
We conclude that polymorphisms in the EFBN2 gene on chromosome 13q33 were not strongly associated with ESRD as defined by the chromosome 13 linkage peak observed in African-American families enriched for members with severe nephropathy, although two haplotypes in EFNB2 were nominally associated with all-cause ESRD. Additional gene(s) in this region likely contribute to ESRD susceptibility and efforts to identify these genes should receive high priority. Detection of the genes underlying non-diabetic or hypertension-associated ESRD, such as chromogranin A [25] , may allow us to determine why select individuals with high blood pressure ultimately develop ESRD, as well as identify novel pathways for intervention to prevent hypertension-associated renal failure. 
